JOSEPH P REO
Pharmacy in Lakeland, TN
License number
New Jersey 28RI01570500
Issued Date
Jan 10, 1979
Expiration Date
Apr 30, 2017
Category
Pharmacy
Type
Pharmacist
Address
Address
Lakeland, TN
Professional information
Phenylephrine Pharmaceutical Formulations And Compositions For Colonic Absorption
US Patent:
2008002, Jan 24, 2008
Filed:
Jun 1, 2007
Appl. No.:
11/756881
Inventors:
David Monteith - Pittstown NJ, US
John O'Mullane - Mountain Lakes NJ, US
Joseph Reo - Lakeland TN, US
Robert Nowak - New Providence NJ, US
Jiansheng Wan - Springfield NJ, US
Mohammed Kabir - Lakeland TN, US
Malaz Abutarif - North Brunswick NJ, US
Glenn Fritz - Arlington TN, US
John O'Mullane - Mountain Lakes NJ, US
Joseph Reo - Lakeland TN, US
Robert Nowak - New Providence NJ, US
Jiansheng Wan - Springfield NJ, US
Mohammed Kabir - Lakeland TN, US
Malaz Abutarif - North Brunswick NJ, US
Glenn Fritz - Arlington TN, US
International Classification:
A61K 31/137, A61K 31/4545, A61K 9/14, A61P 11/02, A61P 31/16, A61P 37/00
US Classification:
424497000, 424490000, 514290000, 514653000
Abstract:
The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s). The pharmaceutical composition can further comprise one or more additional therapeutically active agents selected from one or more of the group consisting of antihistamines, analgesics, anti-pyretics, and non-steroidal anti-inflammatory agents. The invention also discloses methods of administering phenylephrine via the colon, thereby increasing the bioavailable amount of therapeutically active unconjugated phenylephrine relative to the total phenylephrine in the plasma.
Therapeutic Solution Concentrate
US Patent:
2012022, Aug 30, 2012
Filed:
Oct 24, 2011
Appl. No.:
13/279801
Inventors:
Joseph P. Reo - Lakeland TN, US
Kevin C. Fowler - Millington TN, US
Mohammed A. Kabir - Cary NC, US
Michael P. Tune - Arlington TN, US
Dennis Nelson - Memphis TN, US
Anna W. Tai - Germantown TN, US
Nanhye Kim - Germantown TN, US
Kevin C. Fowler - Millington TN, US
Mohammed A. Kabir - Cary NC, US
Michael P. Tune - Arlington TN, US
Dennis Nelson - Memphis TN, US
Anna W. Tai - Germantown TN, US
Nanhye Kim - Germantown TN, US
International Classification:
A61K 31/235, A61P 1/10
US Classification:
514544
Abstract:
A concentrated poly(ethylene glycol) solution that has good stability for extended storage is provided for use as a laxative. The concentrated solution comprises water, sodium benzoate, poly(ethylene glycol), and enough acid to yield a solution having a pH at 25° C. in the range 3.0-5.0. It is prepared and packaged to minimize the accumulation of degradation products.
Therapeutic Solution Concentrate
US Patent:
2014008, Mar 20, 2014
Filed:
Nov 22, 2013
Appl. No.:
14/087110
Inventors:
Joseph P. Reo - Lakeland TN, US
Kevin C. Fowler - Millington TN, US
Mohammed A. Kabir - Cary NC, US
Micheal P. Tune - Arlington TN, US
Dennis Nelson - Memphis TN, US
Anna W. Tai - Germantown TN, US
Nanhye Kim - Germantown TN, US
Kevin C. Fowler - Millington TN, US
Mohammed A. Kabir - Cary NC, US
Micheal P. Tune - Arlington TN, US
Dennis Nelson - Memphis TN, US
Anna W. Tai - Germantown TN, US
Nanhye Kim - Germantown TN, US
International Classification:
A61K 47/24, A61K 47/18, A61K 47/12, A61K 31/765, A61K 47/02
US Classification:
514723
Abstract:
A concentrated poly(ethylene glycol) solution that has good stability for extended storage is provided for use as a laxative. The concentrated solution comprises water, sodium benzoate, poly(ethylene glycol), and enough acid to yield a solution having a pH at 25° C. in the range 3.0-5.0. It is prepared and packaged to minimize the accumulation of degradation products.
Taste-Masked Drugs In Rupturing Multiparticulates
US Patent:
8236349, Aug 7, 2012
Filed:
Apr 6, 2005
Appl. No.:
10/599840
Inventors:
Leah Elizabeth Appel - Bend OR, US
Dwayne Thomas Friesen - Bend OR, US
Edward Dennis LaChapelle - Bend OR, US
Sanjay Konagurthu - Bend OR, US
Richard Frank Falk - Bend OR, US
Joseph P. Reo - Lakeland TN, US
Dwayne Thomas Friesen - Bend OR, US
Edward Dennis LaChapelle - Bend OR, US
Sanjay Konagurthu - Bend OR, US
Richard Frank Falk - Bend OR, US
Joseph P. Reo - Lakeland TN, US
Assignee:
Bend Research Inc. - Bend OR
International Classification:
A61K 9/26
US Classification:
424469
Abstract:
A pharmaceutical composition comprises multiparticulates comprising a drug, a matrix material, and swelling agent. In one aspect, the multiparticulates comprise a core comprising a drug, and a coating surrounding the core. The coating is selected from the group consisting of (i) a water-permeable, substantially drug-impermeable coating, and (ii) an anti-enteric coating.
Coatings For Applying Substances Onto Substrate Carrier
US Patent:
2008029, Dec 4, 2008
Filed:
May 30, 2008
Appl. No.:
12/130225
Inventors:
Glenn E. Fritz - Arlington TN, US
Joseph P. Reo - Lakeland TN, US
Mohammed A. Kabir - Lakeland TN, US
Joseph P. Reo - Lakeland TN, US
Mohammed A. Kabir - Lakeland TN, US
International Classification:
A61K 9/48, A61K 31/137, A61K 9/20, A61K 47/10
US Classification:
424451, 514653, 514772, 424464
Abstract:
Compositions of matter containing an active agent, and methods of manufacturing thereof, wherein the method comprises the step of coating a substrate with a coating composition comprising the active agent formulated for immediate release, wherein the coating composition does not contain an appreciable amount of cellulosic materials and preferably comprises polyvinyl alcohol or a polyvinyl alcohol derived copolymer.
Phenylephrine Pharmaceutical Formulations And Compositions For Transmucosal Absorption
US Patent:
2009028, Nov 12, 2009
Filed:
Dec 4, 2008
Appl. No.:
12/328429
Inventors:
David Monteith - Pittstown NJ, US
John O'Mullane - Mountain Lakes NJ, US
Joseph P. Reo - Lakeland TN, US
Dennis Nelson - Memphis TN, US
Jiansheng Wan - Warren NJ, US
Xiaoming Chen - Westfield NJ, US
Mohammed A. Kabir - Lakeland TN, US
John O'Mullane - Mountain Lakes NJ, US
Joseph P. Reo - Lakeland TN, US
Dennis Nelson - Memphis TN, US
Jiansheng Wan - Warren NJ, US
Xiaoming Chen - Westfield NJ, US
Mohammed A. Kabir - Lakeland TN, US
International Classification:
A61K 9/70, A61K 9/00, A61K 9/14, A61K 9/12, A61K 31/137, C07C 215/54
US Classification:
424443, 424400, 424489, 424 45, 514653, 564355
Abstract:
Pharmaceutical compositions comprising phenylephrine or a pharmaceutically acceptable salt thereof and methods for administering the pharmaceutical compositions wherein the composition is formulated for systemic absorption of phenylephrine that avoids first pass metabolism. The compositions of the invention are formulated to be applied to oral mucosa of an animal to allow for enhanced systemic delivery of therapeutically active form of phenylephrine.